COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.
作者信息
Damiani G, Allocco F, Malagoli P
机构信息
Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
出版信息
Clin Exp Dermatol. 2021 Aug;46(6):1106-1108. doi: 10.1111/ced.14631. Epub 2021 Apr 4.
Abstract
摘要
相似文献
1
COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.2019冠状病毒病疫苗接种与接受生物制剂治疗的银屑病患者：来自意大利接种疫苗的医护人员的安全性和有效性的真实证据。
Clin Exp Dermatol. 2021 Aug;46(6):1106-1108. doi: 10.1111/ced.14631. Epub 2021 Apr 4.
2
Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.意大利医护人员感染有症状的 SARS-CoV-2 VOC 202012/01 谱系 B.1.1.7 的暴发调查。
Clin Microbiol Infect. 2021 Aug;27(8):1174.e1-1174.e4. doi: 10.1016/j.cmi.2021.05.007. Epub 2021 May 10.
3
Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.生物制剂治疗的银屑病患者接种 SARS-CoV-2 疫苗的安全性：真实世界经验。
Dermatol Ther. 2022 Jan;35(1):e15177. doi: 10.1111/dth.15177. Epub 2021 Nov 15.
4
Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.疫苗类型和既往 SARS-CoV-2 感染与医护人员接种疫苗后症状和抗体测量的关联。
JAMA Intern Med. 2021 Dec 1;181(12):1660-1662. doi: 10.1001/jamainternmed.2021.4580.
5
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.司库奇尤单抗治疗银屑病有效性和安全性的多中心研究：意大利在新冠疫情期间的16周真实世界经验
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e169-e170. doi: 10.1111/jdv.17003. Epub 2020 Nov 8.
6
Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.BNT162b2疫苗在意大利布雷西亚医护人员中针对SARS-CoV-2 B.1.1.7变体的有效性。
J Infect. 2021 Jul;83(1):e17-e18. doi: 10.1016/j.jinf.2021.04.038. Epub 2021 May 7.
7
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.意大利医护人员对 BNT162b2 mRNA COVID-19 疫苗的反应：3 个月随访。
Intern Emerg Med. 2022 Mar;17(2):481-486. doi: 10.1007/s11739-021-02857-y. Epub 2021 Oct 12.
8
Is the second dose of vaccination useful in previously SARS-CoV-2-infected healthcare workers?既往感染 SARS-CoV-2 的医护人员接种第二剂疫苗是否有效？
Infect Dis Now. 2021 Nov;51(8):673-675. doi: 10.1016/j.idnow.2021.07.001. Epub 2021 Jul 6.
9
Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.BNT162b2 疫苗接种与医护人员中出现有症状和无症状 SARS-CoV-2 感染的相关性。
JAMA. 2021 Jun 22;325(24):2457-2465. doi: 10.1001/jama.2021.7152.
10
Immunosuppressive therapy in dermatology and PML.皮肤科中的免疫抑制疗法与进行性多灶性白质脑病
J Dtsch Dermatol Ges. 2009 Jan;7(1):5. doi: 10.1111/j.1610-0387.2008.06993.x.
引用本文的文献
1
A quantitative investigation in a territory of Italy on citizens' attitudes towards medicines through the COVID-19 pandemic: the importance of possible indirect effects caused by the pandemic.意大利某地区关于公民在新冠疫情期间对药品态度的定量调查：疫情可能造成的间接影响的重要性
J Pharm Policy Pract. 2024 Oct 29;17(1):2418366. doi: 10.1080/20523211.2024.2418366. eCollection 2024.
2
A Study of Humoral Immune Response to Inactivated COVID-19 Vaccine in Patients with Psoriasis Receiving Biologics and Small Molecules.接受生物制剂和小分子药物治疗的银屑病患者对新型冠状病毒灭活疫苗的体液免疫反应研究
Clin Cosmet Investig Dermatol. 2024 Jul 3;17:1565-1568. doi: 10.2147/CCID.S467889. eCollection 2024.
3
Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series.抗白细胞介素17A生物疗法治疗类脂质渐进性坏死性血管病：病例系列报告
Clin Cosmet Investig Dermatol. 2024 May 9;17:1043-1048. doi: 10.2147/CCID.S455903. eCollection 2024.
4
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.COVID-19 感染时的银屑病和生物药物：概述感染风险、血清流行率以及 BNT162b2 疫苗安全性和有效性的小型综述。
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.
5
The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.银屑病、COVID-19 感染与治疗期间疫苗接种的关系。
Adv Exp Med Biol. 2023;1412:339-355. doi: 10.1007/978-3-031-28012-2_18.
6
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis.新冠病毒疫苗在接受生物制剂治疗的银屑病患者中的安全性和有效性。
Psoriasis (Auckl). 2023 Apr 12;13:11-18. doi: 10.2147/PTT.S398135. eCollection 2023.
7
Do Sleep Disorders and Western Diet Influence Psoriasis? A Scoping Review.睡眠障碍和西方饮食会影响银屑病吗？范围综述。
Nutrients. 2022 Oct 16;14(20):4324. doi: 10.3390/nu14204324.
8
Equity Considerations in COVID-19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases.自身免疫性炎性风湿病患者 COVID-19 疫苗接种研究中的公平性考虑。
Arthritis Care Res (Hoboken). 2023 May;75(5):967-974. doi: 10.1002/acr.25034. Epub 2022 Dec 7.
9
Reactivation of pustular psoriasis following mRNA vaccination versus COVID-19 infection: An overlap?: Reply to "Generalized pustular psoriasis following COVID-19" by Dadras MS et al.: Reply to "Generalized pustular psoriasis following COVID-19" by Dadras MS et al.mRNA疫苗接种与新冠病毒感染后脓疱型银屑病的再激活：存在重叠吗？：对Dadras MS等人所著《新冠病毒感染后泛发性脓疱型银屑病》的回复：对Dadras MS等人所著《新冠病毒感染后泛发性脓疱型银屑病》的回复
Dermatol Ther. 2022 Dec;35(12):e15892. doi: 10.1111/dth.15892. Epub 2022 Oct 11.
10
Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics.在接受生物制剂治疗的银屑病患者中，三剂抗SARS-CoV-2 BNT162b2疫苗的免疫原性。
Front Med (Lausanne). 2022 Sep 6;9:961904. doi: 10.3389/fmed.2022.961904. eCollection 2022.
本文引用的文献
1
A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic [Formula: see text].COVID-19 大流行期间使用生物制剂时对疫苗使用理解的基于银屑病患者的调查 [公式：见正文]。
J Cutan Med Surg. 2021 May-Jun;25(3):298-302. doi: 10.1177/1203475421991126. Epub 2021 Jan 27.
2
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.国家银屑病基金会 COVID-19 工作组关于大流行期间银屑病管理的指南：第 2 版-银屑病管理、COVID-19 疫苗和 COVID-19 治疗的进展。
J Am Acad Dermatol. 2021 May;84(5):1254-1268. doi: 10.1016/j.jaad.2020.12.058. Epub 2021 Jan 7.
3
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.接受生物治疗的银屑病患者因 COVID-19 住院和死亡的发生率：意大利北部的经验。
J Allergy Clin Immunol. 2021 Feb;147(2):558-560.e1. doi: 10.1016/j.jaci.2020.10.032. Epub 2020 Nov 5.
4
Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic.新冠疫情全国封锁期间接受生物制剂治疗的银屑病患者的依从性、安全担忧及焦虑：捷克共和国的一项多中心研究
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e682-e684. doi: 10.1111/jdv.16771. Epub 2020 Jul 9.
5
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素17通路抑制生物制剂治疗的银屑病患者发生呼吸道感染和症状的风险：对COVID-19大流行期间决策相关关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
6
COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.COVID-19 知识可预防生物制剂停药：意大利多中心 RED-ZONE 宣言期间的调查数据。
Dermatol Ther. 2020 Jul;33(4):e13508. doi: 10.1111/dth.13508. Epub 2020 May 28.
7
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
8
Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy.银屑病与呼吸合并症：呼出气一氧化氮分数作为一种新方法，用于检测、评估和监测银屑病系统性受累及治疗效果的附加价值。
Biomed Res Int. 2018 Sep 23;2018:3140682. doi: 10.1155/2018/3140682. eCollection 2018.
9
Increased airway inflammation in patients with psoriasis.银屑病患者气道炎症增加。
Br J Dermatol. 2016 Oct;175(4):797-9. doi: 10.1111/bjd.14546. Epub 2016 Jun 20.
Zotero 插件